SELP and cancer: Advanced to RBCM, PM has specifically cancer-targeting ability attributed to the overexpression of P-selectin, which allows PM-cloaked nanodrug to selectively bind to the CD44 receptors upregulated on the surface of cancer cells (Wang et al., 2019).